Enucleation of non-invasive tumors in the proximal pancreas: indications and outcomes compared with standard resections^{*}

Wen-jie LU, Hao-lei CAI, Ma-dong YE, Yu-lian WU, Bin XU^{†‡}

(Department of Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China)

[†]E-mail: xb0426@163.com

Received Jan. 3, 2017; Revision accepted Feb. 12, 2017; Crosschecked Sept. 15, 2017

Abstract: Objective: The aim of this study was to evaluate the safety and efficiency of enucleation (EU) for proximal pancreatic non-invasive neoplasms. Methods: Patients with solitary non-invasive neoplasms in the proximal pancreas from January 1998 to April 2014 at the Second Affiliated Hospital of Zhejiang University, Hangzhou, China were included. Different operations and outcomes were analyzed. Results: A total of 123 patients were enrolled. Forty patients (32.5%) underwent EU including 18 patients who had tumors close to the main pancreatic duct (MPD). Sixty-one patients (49.6%) had pancreaticoduodenectomy (PD) performed and 22 (17.9%) underwent central pancreatectomy (CP). Pathological outcomes included neuroendocrine tumors, cystic lesions, and solid pseudopapillary tumors. Operation time, intra-operative blood loss, and duration of hospital stay were significantly reduced in the EU group. PD was associated with the greatest complication rate (55.7%), followed by EU (50%) and CP (40.9%), though the pancreatic fistula rate after EU was the highest (50%), especially in patients with tumors larger than 3 cm and tumors close to the MPD. EU had advantages in the preservation of pancreatic parenchyma and endocrine and exocrine function. Conclusions: EU can be carried out safely and effectively for tumors in the proximal pancreas with improved outcomes compared with standard resections, even if the tumor is larger than 3 cm and close to the MPD.

Key words: Enucleation; Pancreatic fistula; Pancreaticoduodenectomy; Central pancreatectomy
<http://dx.doi.org/10.1631/jzus.B1600597>

CLC number: R735.9

1 Introduction

Benign and low-grade malignant tumors of the pancreas, including most cystic pancreatic lesions, neuro-endocrine tumors (NETs), and tumors with other various pathologies, are now being discovered more and more in pancreatic centers. When located in the proximal pancreas, these tumors have been traditionally treated with standard resections such as pancreaticoduodenectomies (PDs). Though low mortality

at high-volume medical centers has been achieved (Ho and Heslin, 2003), PDs are still associated with high postoperative morbidity and exo- and endocrine dysfunction (Ghaneh and Neoptolemos, 1999; Grobmyer *et al.*, 2007; Tran *et al.*, 2009). Long-term biliary and pancreatic anastomotic complications following PDs have also been noted (Reid-Lombardo *et al.*, 2007). The amount of resected pancreatic parenchyma largely affects postoperative quality of life of the patients, especially for young patients with a long life expectancy. In the last decade, with its parenchyma-preserving nature and reduced operative invasion, tumor enucleation (EU) serves as an alternative approach to standard resections. Favorable results on surgical outcomes and postoperative pancreatic function have been reported in patients with benign and low-grade malignant tumors after EU

[‡] Corresponding author

^{*} Project supported by the National Natural Science Foundation of China (Nos. 30672072 and 30872531), the Foundation of Science and Technology Department of Zhejiang Province, China (Nos. 2014C33187), and the National High-Tech R&D Program (863) of China (No. 2007AA02Z476)

ORCID: Bin XU, <http://orcid.org/0000-0002-0027-3039>

© Zhejiang University and Springer-Verlag GmbH Germany 2017

(Talamini *et al.*, 1998; Pitt *et al.*, 2009; Hackert *et al.*, 2011). EU has proved to be a safe and adequate procedure for small low-grade neuroendocrine tumors (NETs) and serous cystadenomas (SCAs) (Talamini *et al.*, 1998; Crippa *et al.*, 2010; Hackert *et al.*, 2011; Zhang *et al.*, 2013). EUs of mucinous cystic neoplasms (MCNs), solid pseudopapillary tumors (SPTs), and branch-duct intraductal papillary mucinous neoplasms (IPMNs) have also been reported (Sciaudone *et al.*, 2000; Papavramidis and Papavramidis, 2005; Hackert *et al.*, 2011). However, several studies have reported a high incidence of pancreatic fistula (PF) after EU (Crippa *et al.*, 2007; Hackert *et al.*, 2011; Zhang *et al.*, 2013). The most important complication was damage to the main pancreatic duct (MPD). Considering the potential risk of fistula, large tumors (tumor size larger than 3 cm) and proximity to MPD were generally accepted as contraindications for EUs. Nevertheless, nearly one third of pancreatic benign and borderline tumors arise from the proximal pancreas and may have a close relationship with MPD and the conjunction area of MPD and common bile duct (CBD). Additionally, small tumors are usually asymptomatic, and the mean sizes of benign and low-grade malignant tumors are larger than 3 cm when discovered (Valsangkar *et al.*, 2012). In this study, we focused on the possibility of EU for patients with proximal pancreatic tumors larger than 3 cm and close to the MPD, by evaluating the indications, surgical outcomes, and long-term complications of patients undergoing proximal pancreatic tumor EUs and comparing this approach with standard resections including PDs and central pancreatectomies (CPs).

2 Materials and methods

2.1 Patients and data collection

Data of patients undergoing proximal pancreatic surgery for benign and low-grade malignant neoplasm between January 1998 and June 2014 were collected from an electronic database of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Enrolled benign and low-grade malignant tumors included cystic adenomas, SPTs, NETs, and other pathologically proved non-invasive lesions. Only solitary tumor and lesions arising from the pancreatic parenchyma were included. A total of

126 patients were identified; two patients whose tumors arose from extrapancreatic tissue and one IPMN patient who underwent total pancreatectomy were excluded. Consequently, 123 patients were included.

Demographics, clinical presentation, preoperative evaluation, and intraoperative details such as the duration of the procedure and blood loss were collected. Postoperative complications and length of hospital stay as well as pathological data were also recorded.

2.2 Surgical procedures

Preoperative diagnostic and staging studies including trans-abdominal ultrasound, contrast-enhanced computed tomography (CT) scan, or magnetic resonance imaging (MRI) were performed for all patients. The surgical procedures of EU have been described in a previous publication (Lu *et al.*, 2012). For tumors in the head and uncinate process, the surgeon would palpate the tumor with Kocher's maneuver to evaluate the risk and possibility of EU, followed by careful dissection of proximal pancreas, gastroduodenal artery and superior mesenteric vein. In some patients, intraoperative ultrasonography was performed to confirm the location of the tumor, exclude synchronous multifocal tumors, and clarify possible tumor adherence to the pancreatic duct. A precise EU of the mass along the border of the tumor was carried out after mobilization of the distal pancreas. A Foley catheter was inserted into CBD to avoid injuries if the mass was adjacent to the confluence region. Cholangiopancreatography with methylene blue would be performed to confirm the integrity of the MPD and CBD. For patients proving to have injury to the MPD or CBD, the duct would be repaired or reconstructed with polypropylene sutures. For severe MPD injury, a fine silicon tube was inserted into MPD as a stent, with the other side passing across the papilla into the duodenal cavity, and was fixed by soluble suture. Two or more drain tubes were placed near the wound surface of the proximal pancreas. A frozen section of the tumor lesion was performed in all patients to exclude invasive tumors. Invasive tumor, massive disruption of proximal pancreas and unreparable MPD injury are considered to be contraindications of EU and a standard procedure such as PD or middle segment resection was performed alternatively. Surgical techniques are demonstrated in Fig. 1.

Fig. 1 Surgical techniques of enucleation (EU)

(a) Dissect pancreatic head to evaluate the risk and possibility of EU and reconstruction (black arrow: tumor; blue arrow: duodenum). (b) Precise EU of the mass along the border of the tumor. (c) Check whether there is injury to common bile duct (green arrow) by methylene blue cholangiopancreatography and if there is injury to the common pancreatic duct with visible pancreatic juice leakage, repair or reconstruct it with polypropylene suture (yellow arrow). Blue arrow indicates duodenum. (d) For severe main pancreatic duct injury, a fine silicon tube is inserted into main pancreatic duct (MPD) as a stent, with the other side into duodenum through papilla, fixed with soluble suture (Note: for interpretation of the references to color in this figure legend, the reader is referred to the web version of this article)

PDs were performed with standardized resection and reconstruction of end-to-side two-layer duct-to-mucosa pancreaticojejunostomy, end-to-side one-layer hepaticojejunostomy, and antecolic one-layer end-to-side gastrojejunostomy. For patients who performed CPs, the proximal edge of pancreatic neck was sutured up with polypropylene, and a Roux-Y anastomosis for the distal edge with the jejunum was performed. Resection margin was also examined by frozen section to ensure a tumor-free cut surface. One laparoscopic EU and two laparoscopic PDs were included and all other surgeries carried out in an open way. All surgical procedures were performed by, or under the supervision of, senior surgeons.

2.3 Postoperative management

Empirical antibiotics and octreotide were administered postoperatively, depending on patients' condition, laboratory results, and drainage volume. Enteral nutrition routinely began on postoperative day (POD) 3. The volume and the amylase level of the drainage were monitored and recorded. For patients with postoperative PF and signs of intra-abdominal infection, in situ continuous lavage using a fine long silicon tube through the drain tube was performed (Dong *et al.*, 2008). The drains would be removed when the drainage volume was less than 20 ml per 24 h, with no or little intra-abdomen fluid accumulation confirmed by ultrasonography or CT scan.

Postoperative complications were recorded and evaluated. PF was defined as any volume of drainage on or after the third POD with amylase content greater than three times the upper normal limit of serum level. Grades of fistula severity were identified according to the International Study Group of Pancreatic Fistula (ISGPF) (Bassi *et al.*, 2005). Delayed gastric emptying (DGE) was defined as nasogastric tube being required for longer than 4 d, or reinsertion after POD 3, combined with at least one of the following: unable to tolerate solid oral intake by POD 7, vomiting, gastric distension, and use of prokinetics (Wente *et al.*, 2007b). Postpancreatectomy hemorrhage was identified and classified according to ISGPF definition (Wente *et al.*, 2007a). Perioperative mortality was defined as death in hospital or within 30 d.

2.4 Follow-up

Follow-up was achieved through outpatient medical records and telephone contact, and consisted of clinical, radiological, and laboratory assessments. Tumor recurrence and long-term exocrine and endocrine impairments were evaluated. The presence of new-onset or worsening diabetes was confirmed by measuring serum glucose levels and oral glucose tolerance testing. New-onset exocrine insufficiency was defined by the development of steatorrhea and weight loss, requiring oral pancreatic enzyme supplementation in the absence of tumor recurrence. CT or MRI was routinely applied during follow-up to rule out tumor recurrence and nodal metastasis.

2.5 Statistical analysis

Results were reported as mean±standard deviation (SD) or median (range) as appropriate. Continuous variables such as tumor size, operation time, and age at the time of diagnosis, were compared with Student's *t*-test or the Mann-Whitney *U* test. χ^2 and Fisher's exact tests were used to compare categorical data. $P<0.05$ was considered statistically significant. SPSS statistical software Version 13.0 (Chicago, IL, USA) was used for statistical analysis.

3 Results

3.1 Demographic characteristics

From January 1998 to June 2014, 123 patients underwent surgical resections of a benign or low-

grade malignant tumor in the proximal pancreas. Surgical procedures performed included EU, PD, and CP. The procedures performed on the patients were decided by the surgeon according to preoperative examinations and explorations during the operation. Evolving patterns of surgical procedures are shown in Fig. 2. Nearly one-third of patients ($n=40$, 32.5%) underwent EU. PD and CP were performed in 61 (49.6%) and 22 (17.9%) patients, respectively. The median follow-up time was 46 months, ranging from 2 to 192 months.

Fig. 2 Evolving patterns of surgical procedures
EU: enucleation; PD: pancreaticoduodenectomy; CP: central pancreatectomy

For patients undergoing EU, the mean age at time of operation was 46 years (range, 14 to 75 years). Twenty-one (52.5%) patients were female and 25 (62.5%) patients presented with symptoms. Average diameter of tumor was (31.1 ± 25.0) mm. Large tumors, defined as tumor diameter >3 cm, were found in 14 patients (35.0%). Pathological outcomes for EU included NETs, SCAs, SPTs, and MCNs. Other histopathology found included two lipomas and one hemangioma. Nearly two thirds of tumors (65.0%) were located in the head or the uncinate process of the pancreas. Tumor in the neck and junction parts of the head and neck constituted 27.5% and 7.5% of the cases, respectively. No significant differences regarding gender, age at the time of diagnosis, American Society of Anesthesiologists (ASA) classification, mean tumor size, or sites involved between patients who accepted different operations were found. Data on patients' demographic characteristics are shown in Table 1.

Table 1 Patients' characteristics

Parameter	EU	PD	CP
Number of patients	40	61	22
Gender, female (%)	52.5	47.5	86.4
Mean age (range) (year)	46 (14–75)	54 (15–81)	46 (20–76)
Symptomatic (%)	62.5	52.4	40.9
ASA classification (%)			
I	42.5	31.1	59.1
II	55.0	59.0	40.9
III	2.5	9.8	0
Mean size, $\pm$ SD (mm)	31.1 $\pm$ 25.0	39.9 $\pm$ 22.0	34.1 $\pm$ 18.6
Histology, <i>n</i> (%)			
NETs	25 (62.5%)	15 (26.2%)**	7 (31.8%)*
SCAs	5 (12.5%)	12 (19.7%)	5 (22.7%)
SPTs	5 (12.5%)	12 (19.7%)	9 (40.9%)
MCNs	2 (5.0%)	5 (9.8%)	1 (4.5%)
IPMNs	0	10 (16.4%)*	0
Others	3 (7.5%)	7 (11.5%)	0
Site involved, <i>n</i> (%)			
Head/uncinate process	26 (65.0%)	48 (78.7%)	4 (18.2%)**
Neck	11 (27.5%)	4 (6.6%)**	18 (81.8%)**
Junction of head and neck	3 (7.5%)	9 (14.8%)	0
Median follow-up (range) (month)	50 (3–192)	40 (2–167)	39 (2–168)

EU, enucleation; PD, pancreaticoduodenectomy; CP, central pancreatectomy; ASA, American Society of Anesthesiologists; NET, neuroendocrine tumors; SCA, serous cystadenoma; SPT, solid pseudopapillary tumor; MCN, mucinous cystic neoplasm; IPMN, intraductal papillary mucinous neoplasm. Data are expressed as number, percent, number (percent), mean $\pm$ SD, or median (range).

* $P<0.05$, ** $P<0.01$ vs. EU

3.2 Surgical outcomes and postoperative complications

Operation time, intraoperative blood loss, and duration of hospital stay were significantly reduced in the EU group compared with the PD and CP groups. One patient had a second surgery due to choleperitonitis after tumor EU. The reoperation rates were 11.5%

and 9.1% in the PD and CP groups, respectively. The reoperation reasons included fistula and sequent infection, intra-abdominal bleeding, and bowel obstruction. There was no mortality after EU or CP, but following PD, one patient died due to multiple organ failure. Relevant data are demonstrated in Table 2.

At least one complication was experienced by 40%–55% of the patients, depending on the surgical procedure performed. PD was associated with the greatest complication rate (55.7%), followed by EU (50.0%) and CP (40.9%). The complication pattern varies with different procedures. PF was more frequently seen in patients after EU (50.0%), compared with 27.9% ($P<0.05$ vs. EU) and 31.8% in the PD and CP groups, respectively. Most fistulas after EU were symptomatic (42.5%), and all recovered after in situ continuous abdominal lavage with uneventful courses. In contrast, though ISGPF type B fistulas less commonly occurred after PD (16.4%, $P<0.05$ vs. EU) and CP (22.7%), surgical reoperations were indicated in two patients after PD due to an ISGPF type C fistula. Postoperative bleeding (including early and delayed hemorrhages) was more frequent, but not significantly so, in the PD group than in the other two procedure groups. Five patients in the PD group and two patients in the CP group had laparotomy hemostasis. Almost one fifth of patients experienced DGE after PD. EU and CP had DGE rates of 7.5% ($P<0.05$ vs. PD) and 9.1%, respectively. In terms of long-term complications, no patient developed exo- or endocrine dysfunction after tumor EU. In comparison, new-onset diabetes or worsening diabetes occurred in 14.8% ($P<0.05$ vs. EU) and 9.1% (not significant, vs. EU) of patients after PD and CP, respectively. Exocrine deficiency was a more prevalent long-term consequence after PD. Of the 61 patients, a total of 19 (31.1%, $P<0.01$ vs. EU) patients required oral pancreatic enzyme supplementation. The rates of bile leakage, wound infection, abdominal abscess, pneumonia, cardiac events were similar among the three groups. Table 3 summarizes the data on postoperative complications.

Table 2 Operative outcomes

Group	<i>n</i>	Operation time ^a (min)	Blood loss ^a (ml)	Complication (%)	Hospital mortality (%)	Reoperation rate (%)	Median hospital stay ^a (d)
EU	40	155 $\pm$ 50	183 $\pm$ 156	50.0	0	2.5	15 $\pm$ 13
PD	61	365 $\pm$ 109**	543 $\pm$ 413**	55.7	1.6	11.5	24 $\pm$ 26**
CP	22	270 $\pm$ 55**	291 $\pm$ 135**	40.9	0	9.1	21 $\pm$ 26*

EU, enucleation; PD, pancreaticoduodenectomy; CP, central pancreatectomy; *n*, number of patients. ^a Data are expressed as mean $\pm$ SD.

* $P<0.05$, ** $P<0.01$ vs. EU

3.3 Enucleation of tumor adjacent to main pancreatic duct

Among 40 patients undergoing EU, the tumors of 18 patients (18/40, 45.0%) were close to the MPD. The term “close” we used was defined as direct contact of the tumor with the MPD on preoperative scans, or exposure of the MPD after EU of the tumor. The median diameter of the neoplasms was 40 (10–100) mm.

About 61.1% (11/18) patients presented with a tumor large than 3 cm. As shown in Table 4, of the 18 patients, six cases with tumors close to CBD simultaneously underwent cholecystectomies. Six patients had MPD injuries repaired with polypropylene intraoperatively. CBD injury was found in two patients, and for those CBD neoplasty and T-tube drainage were performed.

Table 3 Postoperative complications

Group	n	PF (%)				Postoperative bleeding (%)	DGE (%)	GI anastomosis fistula (%)
		Overall	A	B	C			
EU	40	50.0	7.5	42.5	0	2.5	7.5	0
PD	61	27.9*	9.8	14.8**	3.3	14.8	19.7	8.2
CP	22	31.8	9.1	22.7	0	18.2	9.1	0

Group	Bile leakage (%)	Wound infection (%)	Abdominal abscess (%)	Pneumonia (%)	Cardiac dysfunction (%)	Endocrine dysfunction (%)	Exocrine dysfunction (%)
EU	2.5	2.5	5.0	0	0	0	0
PD	8.2	0	14.8	9.8*	3.3	14.8*	31.1**
CP	0	4.5	9.1	4.5	0	18.4	4.5

EU, enucleation; PD, pancreaticoduodenectomy; CP, central pancreatectomy; n, number of patients; PF, pancreatic fistula; DGE, delay gastric empty; GI, gastrointestinal. * $P<0.05$, ** $P<0.01$ vs. EU

Table 4 Patients' characteristics and complications regarding tumors adjacent to main pancreatic duct

No.	Sex	Age (year)	Follow-up (month)	Size (cm)	His.	CC	CBD injury	MPD injury	DT (d)	PF	PKD (ml/24 h)	DGE	RL
1	M	57	162	1.5	NET				39	B	1500	Y	
2	M	67	159	3.0	NET	Y		Y	10	A	430		
3	F	29	117	10.0	SPT				45	B	1060	Y	
4	M	30	94	1.5	NET				25	B	250		
5	M	56	89	2.0	NET				5				
6	F	40	79	5.0	SCA	Y		Y	62	B	1200	Y	
7	M	37	67	6.0	SCA	Y			165	B	300		
8	M	28	66	2.7	NET				72	B	300		
9	F	16	61	5.0	SPT				23	B	300		
10	F	46	61	3.0	NET				11				
11	M	54	60	1.0	NET				10				
12	F	14	59	8.0	SPT	Y	Y	Y	281	B	1000		Y
13	F	49	50	4.0	SCA			Y	51	B	600		
14	F	30	28	6.0	SCA			Y	31	B	1120		
15	M	54	17	8.0	HA	Y	Y		13				
16	F	53	6	3.9	NET				10				
17	M	57	3	8.0	Lipoma			Y	17	B	800		
18	F	54	3	4.0	NET	Y			9				

M, male; F, female; His., histology; NET, neuroendocrine tumors; SPT, solid pseudopapillary tumor; SCA, serous cystadenoma; HA, hemangioma; CC, cholecystectomy; Y, yes; CBD, common bile duct; MPD, main pancreatic duct; DT, drainage time; PF, pancreatic fistula; PKD, peak drainage; DGE, delayed gastric empty; RL, relaparotomy

Postoperative complications of these 18 patients are listed in Table 4. Average operation time and estimated blood loss were (152±50) min and (189±197) ml, respectively. A PF developed in 12 (12/18, 66.7%) patients, including all the 6 cases which had MPDs injured and repaired, but none had signs of severe infection or sepsis. Median peak drainage volume was 800 ml/24 h, ranging from 250 to 1500 ml/24 h. The majority are classified as ISGPF type B fistula because of persistent and high-output drainage. Clinical conditions of these 12 patients are extremely well except for prolonged drainage time ((48.83±69.26) d). DGE was also found in three patients (3/18, 16.7%). Reoperation was required in one patient due to choleperitonitis caused by an accidental drop of the T-tube on POD 6.

3.4 Effects of tumor size on surgical outcomes and strategies

Of the 40 patients undergoing EU, patients with large tumors (larger than 3 cm) showed higher possibilities of MPD injury and fistula occurrence than those with small ones (35.7% vs. 3.8%, $P<0.05$; 71.4% vs. 38.5%, $P<0.05$). Also, large tumor patients kept drainage tubes for a longer period of time. However, no significant difference regarding operation time or blood loss was noticed between these two subgroups (Table 5).

There was a step-wise increase in the number of patients who underwent PDs and a parallel decrease in the proportion of patients who had EUs in line with the increase of tumor size. When tumor sizes were no larger than 1 cm, predilection for EU was most obvious. A total of 75.0% (9/12) of patients had EUs. Standard resections were done in the other three patients. Of 52 patients with tumor diameter between 1 and 3 cm, the spectrum of surgical strategies was significant. PDs were performed in nearly 50.0% of patients. Tumor EUs were carried out in 17 (32.6%) patients, followed by CPs in 12 (20.7%) patients. For

59 patients whose tumors were larger than 3 cm, 23.7% of patients underwent EUs, and 36 (61.0%) and 9 (15.2%) patients underwent PDs and CPs, respectively (Fig. 3).

Fig. 3 Percentages of surgical procedures varied with tumor size

EU, enucleation; PD, pancreaticoduodenectomy; CP, central pancreatectomy

3.5 Follow-up

The median follow-up time for the EU and standard resection groups was 50 and 40 months, ranging from 3 to 192 and 2 to 168 months, respectively. Of the 47 patients with NETs, two were lost during follow-up. Of the remaining 45 patients, the median follow-up was 43 months (range, 3 to 192 months). No recurrences or metastases were observed in these patients. Regarding follow-up of the 44 patients with IPMN, MCN, and SPT, the median follow-up time was 39 months (range, 2 to 121 months); again no recurrence was discovered.

4 Discussion

PDs and CPs, as standard procedures for proximal pancreatic tumors, have been performed on patients for decades. Considering the good prognosis

Table 5 Postoperative complications regarding tumor size

Tumor size (cm)	n	Operation time (min)	Blood loss (ml)	Hospital Stay (d)	MPD injury (%)	PF (%)			DC with drains (%)	DGE (%)
						Overall	A	B		
≤3	26	151±52	177±144	15±8	1 (3.8%)	10 (38.5%)	2 (11.5%)	8 (30.8%)	6 (23.1%)	1 (3.8%)
>3	14	163±47	193±183	24±20	5 (35.7%)*	10 (71.4%)*	1 (7.1%)	9 (64.3%)*	9 (64.3%)*	3 (21.4%)

n, number of patients; MPD, main pancreatic duct; PF, pancreatic fistula; DC, discharge; DGE, delayed gastric empty. * $P<0.05$ vs. tumor size ≤3 cm

of most benign and low-grade malignant tumors and their predilection for the young or middle-aged population (Valsangkar *et al.*, 2012), patients could benefit more from parenchyma sparing and “no gastrointestinal tract disturbance” surgical procedures such as tumor EU. EU, first reported in 1898 by Ernesto Tricomi (Howard and Hess, 2002), has been widely accepted as an alternative procedure for benign and low-grade malignant pancreatic tumors including endocrine tumors (Ramage *et al.*, 2005; Norton, 2006; Crippa *et al.*, 2007; Falconi *et al.*, 2010; Hackert *et al.*, 2011; Zhang *et al.*, 2013), SCAs, MCNs, SPTs, branch-duct IPMNs, pseudocysts, and so forth (Talamini *et al.*, 1998; Kiely *et al.*, 2003; Madan *et al.*, 2004; Papavramidis and Papavramidis, 2005; Crippa *et al.*, 2007; Ge *et al.*, 2010; Hackert *et al.*, 2011; Turrini *et al.*, 2011; Zhang *et al.*, 2013). EU has proved to be a procedure characterized by less operation time and blood loss, faster recovery, and preserving more of the pancreas parenchyma, compared with standard procedures (Casadei *et al.*, 2010; Falconi *et al.*, 2010; Hackert *et al.*, 2011; Yan *et al.*, 2015). Yet there are some problems for the application of EUs, including PF afterwards and indications and contraindications for EUs. In this study, we analyzed patients who had proximal pancreatic operations over the last 16 years to reveal the indications and outcomes of tumor EUs, and compared these results with standard resections. This series, to our knowledge, represents the first and largest series regarding EU of large tumors adjacent to MPD.

For EU of pancreatic tumors, PF is still considered to be the most frequent complication that contributes substantially to surgical morbidity rate and prolongs hospital stay. An overall PF rate of 50% after tumor EU was observed in this series, in comparison with 20% to 60% in other studies (Crippa *et al.*, 2007; Pitt *et al.*, 2009; Falconi *et al.*, 2010; Hackert *et al.*, 2011; Zhang *et al.*, 2013). Normal underlying pancreatic texture partly contributes to more frequent PF occurrence. In addition, common risk factors identified for EU associated with PF in other literature included: soft texture of remnant pancreas, MPD diameter less than 3 mm, distance between tumor and MPD, body mass index, New York Heart Association (NYHA) class II or III, operation time ≥ 180 min, certain inherited genetic diseases, and deep EU (Goasguen *et al.*, 2009; Brient

et al., 2012; Inchauste *et al.*, 2012; Zhang *et al.*, 2013; Heeger *et al.*, 2014; Atema *et al.*, 2015).

Given the fact that post-operative PF is related to tumor size and distance to the MPD, for most previous reports, pancreatic EUs were mainly performed in small or outwardly-growing tumors. In a review of 709 patients who had EU between 1991 and 2012, the mean tumor size was 2.4 cm (Beger *et al.*, 2014). Upper limitation of 2 or 3 cm is a well-accepted size criterion for application of the EU technique. In our series, 40 patients had an average tumor diameter of (31.1 ± 25.0) mm under EU. Tumors with diameters over 3 cm were found in 14 patients and 78.6% (11/14) of them were close to the MPD. We noted that overall postoperative PF and ISGPF grade B fistula rates correlate well with tumor size and its relationship with the MPD. Higher fistula rates were observed in the large tumor subgroup (10/14, 71.4%) and tumors adjacent to the MPD (11/18, 61.1%). Thus the higher fistula rate and the fact that there were more ISGPF grade B cases in this cohort are presumably attributable to the inclusion of more patients with a large tumor with proximity to the pancreatic duct. Although EUs were related to a higher incidence of fistulas compared to standard resections, all fistulas developed after EU were defined as ISGPF grade A/B fistulas. Symptomatic fistulas were all successfully treated by *in situ* high-volume modified continuous lavage (Dong *et al.*, 2008). No further surgical treatment was indicated. Therefore, despite a longer drainage time, a more important issue here is that PF following EU was less complicated than other standard resections, because the pancreatic juice is kept out of contact with jejunal fluid in patients after EUs.

Distance to the MPD is also a factor to be considered in performing EU with a concern of duct injuries. A distance of 2–3 mm between tumor and the MPD was proven by several reports to be the criterion for a safe EU (Pitt *et al.*, 2009; Casadei *et al.*, 2010). Heeger *et al.* (2014) recently published a study on deep EU with tumor proximity to MPD, showing that compared with standard EU, deep EU was associated with a high rate of fistulas and morbidities. In addition, the distance between tumor and MPD negatively influenced the occurrence of ISGPF grades B and C fistulas. We went a step further in our practice. The application of EU was expanded to tumors with direct involvement with the MPD, as long as duct injuries

could be repaired. For patients with irreparable MPD injury or massive disruption of the proximal pancreas, standard resections were applied. Similar results for PFs were observed in our studies. Among the 18 patients with a tumor adjacent to the MPD, six patients also underwent MPD repair and reconstruction during the surgery, and CBD neoplasty and T-tube drainage were performed in two patients due to CBD injuries. A total of 12 patients (66.7%), including all the 6 patients who had the MPD injured and repaired, developed symptomatic and high-output fistulas after surgery. This is comparable with ISGPF grade B/C rate of 70% in other research (Heeger *et al.*, 2014). All 12 patients recovered after in situ high-volume modified continuous lavage and simple drainage. Thus, repairable damage to MPD should not be considered as contraindications for EU.

Nevertheless, another issue that needs to be considered is the possibility of malignancy in a large tumor group. Oncological adequacy of EU for NETs is still debated. According to the National Comprehensive Cancer Network (NCCN) guidelines, a NET larger than 2 cm should be treated with standard resections, considering the potential possibility of malignancy (Kulke *et al.*, 2012). Some other authors argued that tumor size was not associated with the probability of nodal metastases (Ferrone *et al.*, 2007; Falconi *et al.*, 2010). In this sense, the necessity for lymph node sampling needs to be further investigated. In our practice, EUs were administered in 25 NET patients with a mean tumor size of 18.3 mm. Tumors with diameters larger than 2 cm were found in seven patients. None had proper lymphadenectomy. Final histological grading of the 25 patients gave all G1. Up to now, no evidence of tumor recurrence or nodal metastasis was found. Even so, strict follow-up of these patients is strongly recommended. Patients with a low malignancy tumor, such as MCNs and SPTs, also had a high likelihood of malignant transformation. In situ carcinoma was reported in 19.2% and 17.3%–36.0% of resected SPTs and MCNs, respectively (Beger *et al.*, 2014), and tumor size at presentation was related to malignant disease (Butte *et al.*, 2011). Thus some articles proposed that EU might be indicated for small low malignancy tumors localized in the periphery of the pancreas (Zhang *et al.*, 2013). In our study, in follow-up of two patients with MCNs (mean size: 60.0 mm) and five with SPTs (mean size:

53.4 mm), subsequent EU did not show signs of tumor recurrence. These results were supported by a few other studies regarding treating MCNs and SPTs with EU (le Borgne *et al.*, 1999; Kiely *et al.*, 2003; Cauley *et al.*, 2012). Reoperation was warranted if a positive margin or a malignant tumor was found on final pathology. With an IPMN lesion up to 2–3 cm, 25%–30% showed premalignant or malignant features, and EUs were not adequate for these patients (Schmidt *et al.*, 2007).

5 Conclusions

Proximal pancreatic tumor EU can be carried out with results better than those with standard resection, in terms of operation time, blood loss, hospital stay, and long-term pancreatic function. Small tumor size correlates well with the possibility for EU and low postoperative fistula rate. Large tumor size and a close relationship to MPD are not absolute contraindications for local EU, though subsequent fistula rate would be high. EU of tumors in the proximal pancreas should be recommended in patients with benign or low-grade malignant tumors.

Compliance with ethics guidelines

Wen-jie LU, Hao-lei CAI, Ma-dong YE, Yu-lian WU, and Bin XU declare that they have no conflict of interest.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study.

References

- Atema, J.J., Jilesen, A.P., Busch, O.R., *et al.*, 2015. Pancreatic fistulae after pancreatic resections for neuroendocrine tumours compared with resections for other lesions. *HPB*, **17**(1):38–45.
<http://dx.doi.org/10.1111/hpb.12319>
- Bassi, C., Dervenis, C., Butturini, G., *et al.*, 2005. Postoperative pancreatic fistula: an international study group (IS-GPF) definition. *Surgery*, **138**(1):8–13.
<http://dx.doi.org/10.1016/j.surg.2005.05.001>
- Beger, H.G., Poch, B., Vasilescu, C., 2014. Benign cystic neoplasm and endocrine tumours of the pancreas—when and how to operate—an overview. *Int. J. Surg.*, **12**(6): 606–614.
<http://dx.doi.org/10.1016/j.ijsu.2014.03.020>

- Brient, C., Regenet, N., Sulpice, L., *et al.*, 2012. Risk factors for postoperative pancreatic fistulization subsequent to enucleation. *J. Gastrointest. Surg.*, **16**(10):1883-1887.
<http://dx.doi.org/10.1007/s11605-012-1971-x>
- Butte, J.M., Brennan, M.F., Gönen, M., *et al.*, 2011. Solid pseudopapillary tumors of the pancreas. Clinical features, surgical outcomes, and long-term survival in 45 consecutive patients from a single center. *J. Gastrointest. Surg.*, **15**(2):350-357.
<http://dx.doi.org/10.1007/s11605-010-1337-1>
- Casadei, R., Ricci, C., Rega, D., *et al.*, 2010. Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? A single-center experience. *Pancreas*, **39**(6):825-828.
<http://dx.doi.org/10.1097/MPA.0b013e3181cf155c>
- Cauley, C.E., Pitt, H.A., Ziegler, K.M., *et al.*, 2012. Pancreatic enucleation: improved outcomes compared to resection. *J. Gastrointest. Surg.*, **16**(7):1347-1353.
<http://dx.doi.org/10.1007/s11605-012-1893-7>
- Crippa, S., Bassi, C., Salvia, R., *et al.*, 2007. Enucleation of pancreatic neoplasms. *Br. J. Surg.*, **94**(10):1254-1259.
<http://dx.doi.org/10.1002/bjs.5833>
- Crippa, S., Boninsegna, L., Partelli, S., *et al.*, 2010. Parenchyma-sparing resections for pancreatic neoplasms. *J. Hepatobiliary Pancreat. Sci.*, **17**(6):782-787.
<http://dx.doi.org/10.1007/s00534-009-0224-1>
- Dong, X., Gao, S.L., Xie, Q.P., *et al.*, 2008. In situ high-volume modified continuous closed and/or open lavage for infected necrotizing pancreatitis. *Pancreas*, **36**(1):44-49.
<http://dx.doi.org/10.1097/mpa.0b013e31812e9688>
- Falconi, M., Zerbi, A., Crippa, S., *et al.*, 2010. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. *Ann. Surg. Oncol.*, **17**(6):1621-1627.
<http://dx.doi.org/10.1245/s10434-010-0949-8>
- Ferrone, C.R., Tang, L.H., Tomlinson, J., *et al.*, 2007. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? *J. Clin. Oncol.*, **25**(35):5609-5615.
<http://dx.doi.org/10.1200/JCO.2007.12.9809>
- Ge, C., Luo, X., Chen, X., *et al.*, 2010. Enucleation of pancreatic cystadenomas. *J. Gastrointest. Surg.*, **14**(1):141-147.
<http://dx.doi.org/10.1007/s11605-009-1023-3>
- Ghaneh, P., Neoptolemos, J.P., 1999. Exocrine pancreatic function following pancreatectomy. *Ann. N. Y. Acad. Sci.*, **880**:308-318.
- Goasguen, N., Bourrier, A., Ponsot, P., *et al.*, 2009. Endoscopic management of pancreatic fistula after distal pancreatectomy and enucleation. *Am. J. Surg.*, **197**(6):715-720.
<http://dx.doi.org/10.1016/j.amjsurg.2008.03.005>
- Grobmyer, S.R., Pieracci, F.M., Allen, P.J., *et al.*, 2007. Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. *J. Am. Coll. Surg.*, **204**(3):356-364.
<http://dx.doi.org/10.1016/j.jamcollsurg.2006.11.017>
- Hackert, T., Hinz, U., Fritz, S., *et al.*, 2011. Enucleation in pancreatic surgery: indications, technique, and outcome compared to standard pancreatic resections. *Langenbeck's Arch. Surg.*, **396**(8):1197-1203.
<http://dx.doi.org/10.1007/s00423-011-0801-z>
- Heeger, K., Falconi, M., Partelli, S., *et al.*, 2014. Increased rate of clinically relevant pancreatic fistula after deep enucleation of small pancreatic tumors. *Langenbeck's Arch. Surg.*, **399**(3):315-321.
<http://dx.doi.org/10.1007/s00423-014-1171-0>
- Ho, V., Heslin, M.J., 2003. Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. *Ann. Surg.*, **237**(4):509-514.
<http://dx.doi.org/10.1097/01.SLA.0000059981.13160.97>
- Howard, J.M., Hess, W., 2002. History of the Pancreas: Mystery of a Hidden Organ. Kluwer Academic/Plenum Publisher, New York.
- Inchauste, S.M., Lanier, B.J., Libutti, S.K., *et al.*, 2012. Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors. *World J. Surg.*, **36**(7):1517-1526.
<http://dx.doi.org/10.1007/s00268-012-1598-9>
- Kiely, J.M., Nakeeb, A., Komorowski, R.A., *et al.*, 2003. Cystic pancreatic neoplasms: enucleate or resect? *J. Gastrointest. Surg.*, **7**(7):890-897.
<http://dx.doi.org/10.1007/s11605-003-0035-7>
- Kulke, M.H., Benson, A.B.3rd, Bergsland, E., *et al.*, 2012. Neuroendocrine tumors. *J. Natl. Compr. Canc. Netw.*, **10**(6):724-764.
- le Borgne, J., de Calan, L., Partensky, C., 1999. Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional retrospective study of 398 cases. French Surgical Association. *Ann. Surg.*, **230**(2):152-161.
- Lu, W.J., Xu, B., Gao, S.L., *et al.*, 2012. Enucleation of benign or borderline pancreatic head tumors adjacent to the common pancreatic duct. *Pancreas*, **41**(2):336-337.
<http://dx.doi.org/10.1097/MPA.0b013e318229b891>
- Madan, A.K., Weldon, C.B., Long, W.P., *et al.*, 2004. Solid and papillary epithelial neoplasm of the pancreas. *J. Surg. Oncol.*, **85**(4):193-198.
<http://dx.doi.org/10.1002/jso.20019>
- Norton, J.A., 2006. Surgery for primary pancreatic neuroendocrine tumors. *J. Gastrointest. Surg.*, **10**(3):327-331.
<http://dx.doi.org/10.1016/j.gassur.2005.08.023>
- Papavramidis, T., Papavramidis, S., 2005. Solid pseudopapillary tumors of the pancreas: review of 718 patients reported in English literature. *J. Am. Coll. Surg.*, **200**(6):965-972.
<http://dx.doi.org/10.1016/j.jamcollsurg.2005.02.011>
- Pitt, S.C., Pitt, H.A., Baker, M.S., *et al.*, 2009. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? *J. Gastrointest. Surg.*, **13**(9):1692-1698.
<http://dx.doi.org/10.1007/s11605-009-0946-z>
- Ramage, J.K., Davies, A.H., Ardill, J., *et al.*, 2005. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. *Gut*, **54**:iv1-iv16.
<http://dx.doi.org/10.1136/gut.2004.053314>

- Reid-Lombardo, K.M., Ramos-de la Medin, A., Thomsen, K., et al., 2007. Long-term anastomotic complications after pancreaticoduodenectomy for benign diseases. *J. Gastrointest. Surg.*, **11**(12):1704-1711.
<http://dx.doi.org/10.1007/s11605-007-0369-7>
- Schmidt, C.M., White, P.B., Waters, J.A., et al., 2007. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. *Ann. Surg.*, **246**(4): 644-654.
<http://dx.doi.org/10.1097/SLA.0b013e318155a9e5>
- Sciaudone, G., Perniceni, T., Lévy, P., et al., 2000. Enucleation of intraductal papillary-mucinous tumor of the head of the pancreas. Report of 2 cases. *Gastroenterol. Clin. Biol.*, **24**(1):121-124 (in French).
- Talamini, M.A., Moesinger, R., Yeo, C.J., et al., 1998. Cystadenomas of the pancreas: is enucleation an adequate operation? *Ann. Surg.*, **227**(6):896-903.
- Tran, T.C., van Lanschot, J.J., Bruno, M.J., et al., 2009. Functional changes after pancreatoduodenectomy: diagnosis and treatment. *Pancreatol.*, **9**(6):729-737.
<http://dx.doi.org/10.1159/000264638>
- Turrini, O., Schmidt, C.M., Pitt, H.A., et al., 2011. Side-branch intraductal papillary mucinous neoplasms of the pancreatic head/uncinate: resection or enucleation? *HPB*, **13**(2): 126-131.
<http://dx.doi.org/10.1111/j.1477-2574.2010.00256.x>
- Valsangkar, N.P., Morales-Oyarvide, V., Thayer, S.P., et al., 2012. 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. *Surgery*, **152**(3 Suppl.):S4-S12.
<http://dx.doi.org/10.1016/j.surg.2012.05.033>
- Wente, M.N., Veit, J.A., Bassi, C., et al., 2007a. Postpancreatectomy hemorrhage (PPH)—an International Study Group of Pancreatic Surgery (ISGPS) definition. *Surgery*, **142**(1):20-25.
<http://dx.doi.org/10.1016/j.surg.2007.02.001>
- Wente, M.N., Bassi, C., Dervenis, C., et al., 2007b. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). *Surgery*, **142**(5):761-768.
<http://dx.doi.org/10.1016/j.surg.2007.05.005>

- Yan, J.F., Kuang, T.T., Ji, D.Y., et al., 2015. Laparoscopic versus open distal pancreatectomy for benign or premalignant pancreatic neoplasms: a two-center comparative study. *J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.)*, **16**(7):573-579.
<http://dx.doi.org/10.1631/jzus.B1400257>
- Zhang, T., Xu, J., Wang, T., et al., 2013. Enucleation of pancreatic lesions: indications, outcomes, and risk factors for clinical pancreatic fistula. *J. Gastrointest. Surg.*, **17**(12): 2099-2104.
<http://dx.doi.org/10.1007/s11605-013-2355-6>

中文概要

题目：近端胰腺非侵袭性肿瘤剝除手术：指征及与传统标准剝除手术效果比较

目的：评价近端胰腺非侵袭性肿瘤剝除手术的安全性与有效性。

创新点：以目前为止最大样本量的近端胰腺非侵袭性肿瘤的剝除手术的数据分析，证实了剝除手术在这类患者中的安全性和有效性，即使肿瘤直径>3 cm或临近主胰管肿瘤。并且首次报道和证实了在这些患者剝除手术中发生主胰管损伤，进行主胰管修补与支架置入是安全有效的。分析了同期进行不同手术方式患者的肿瘤资料，阐明了肿瘤大小影响手术策略的制定。

方法：详细对比了剝除手术和传统的胰十二指肠切除术以及胰腺中段切除术的术前情况、术中情况、术后并发症资料（表 1~3），尤其详细描述了临近主胰管和主胰管有损伤的患者剝除手术后并发症情况（表 4）。同时，附图说明了主胰管修补手术方法（图 1）。

结论：近端胰腺非侵袭性肿瘤的剝除手术是安全有效的，应该是这类患者手术治疗的首选推荐方式，在大肿瘤和临近主胰管的肿瘤患者中也可施行。

关键词：剝除；胰痿；胰十二指肠切除术；胰腺中段切除